---
figid: PMC7916216__cancers-13-00711-g002
figlink: pmc/articles/PMC7916216/figure/cancers-13-00711-f002/
number: Figure 2
caption: 'Direct and indirect effects of radiotherapy, chemotherapy, and protein kinase
  inhibitors on NK cell activity. Radiotherapy (A) and chemotherapy (B) cause cell
  damage, often leading to NK cell impairment, whereas protein kinase inhibitors (C)
  target specific signaling pathways resulting in either increased or decreased NK
  cell activity depending on the pathway involved. These treatments can also induce
  the modulation of various NK cell ligands on tumor cells and the release of damage-associated
  molecular patterns (DAMPs), indirectly affecting NK cell functions. Red arrows:
  inhibitory effects; green arrows: stimulatory effects; blue arrows: indirect effects,
  modulating the tumor cell’s susceptibility to NK-mediated cytolysis. ULBP1-6: UL16
  binding protein 1-6; MICA: MHC class I polypeptide–related sequence; TRAIL: tumor
  necrosis factor-related apoptosis-inducing ligand; HLA: human leukocyte antigen;
  PD-(L)1: programmed cell death protein (ligand) 1, NKG: natural killer receptor;
  NCR: natural cytotoxicity receptors; BRAF: B-rapidly accelerated fibrosarcoma; GSK-3β:
  Glycogen synthase kinase-3β; JAK: Janus kinase.'
pmcid: PMC7916216
papertitle: 'Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on
  Immune Function and Therapeutic Response.'
reftext: Elisa C. Toffoli, et al. Cancers (Basel). 2021 Feb;13(4):711.
pmc_ranked_result_index: '72597'
pathway_score: 0.5844337
filename: cancers-13-00711-g002.jpg
figtitle: Direct and indirect effects of radiotherapy, chemotherapy, and protein kinase
  inhibitors on NK cell activity
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7916216__cancers-13-00711-g002.html
  '@type': Dataset
  description: 'Direct and indirect effects of radiotherapy, chemotherapy, and protein
    kinase inhibitors on NK cell activity. Radiotherapy (A) and chemotherapy (B) cause
    cell damage, often leading to NK cell impairment, whereas protein kinase inhibitors
    (C) target specific signaling pathways resulting in either increased or decreased
    NK cell activity depending on the pathway involved. These treatments can also
    induce the modulation of various NK cell ligands on tumor cells and the release
    of damage-associated molecular patterns (DAMPs), indirectly affecting NK cell
    functions. Red arrows: inhibitory effects; green arrows: stimulatory effects;
    blue arrows: indirect effects, modulating the tumor cell’s susceptibility to NK-mediated
    cytolysis. ULBP1-6: UL16 binding protein 1-6; MICA: MHC class I polypeptide–related
    sequence; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand; HLA:
    human leukocyte antigen; PD-(L)1: programmed cell death protein (ligand) 1, NKG:
    natural killer receptor; NCR: natural cytotoxicity receptors; BRAF: B-rapidly
    accelerated fibrosarcoma; GSK-3β: Glycogen synthase kinase-3β; JAK: Janus kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KLRK1
  - NCR3
  - CXCL16
  - TNFSF10
  - HLA-G
  - MAP6
  - PDCD1
  - BRAF
  - GSK3B
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - ULBP2
  - TAM
  - cancer
genes:
- word: NKG2D,
  symbol: NKG2D
  source: hgnc_alias_symbol
  hgnc_symbol: KLRK1
  entrez: '22914'
- word: NKp30
  symbol: NKp30
  source: hgnc_alias_symbol
  hgnc_symbol: NCR3
  entrez: '259197'
- word: CXCL16
  symbol: CXCL16
  source: hgnc_symbol
  hgnc_symbol: CXCL16
  entrez: '58191'
- word: TRAIL
  symbol: TRAIL
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF10
  entrez: '8743'
- word: HLA-G
  symbol: HLA-G
  source: hgnc_symbol
  hgnc_symbol: HLA-G
  entrez: '3135'
- word: LA-ABC,HLA-G
  symbol: HLA-G
  source: hgnc_symbol
  hgnc_symbol: HLA-G
  entrez: '3135'
- word: TRAIL
  symbol: TRAIL
  source: hgnc_alias_symbol
  hgnc_symbol: TNFSF10
  entrez: '8743'
- word: STOP
  symbol: STOP
  source: hgnc_alias_symbol
  hgnc_symbol: MAP6
  entrez: '4135'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: STOP
  symbol: STOP
  source: hgnc_alias_symbol
  hgnc_symbol: MAP6
  entrez: '4135'
- word: ĮMICA/B,ULBP2
  symbol: ULBP2
  source: hgnc_symbol
  hgnc_symbol: ULBP2
  entrez: '80328'
- word: ULBP2
  symbol: ULBP2
  source: hgnc_symbol
  hgnc_symbol: ULBP2
  entrez: '80328'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
chemicals:
- word: TAM
  source: MESH
  identifier: C419191
diseases:
- word: cancer
  source: MESH
  identifier: D009369
---
